T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.95% |
| 2 | Consumer Discretionary | 13.63% |
| 3 | Financials | 12.8% |
| 4 | Industrials | 12.27% |
| 5 | Technology | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1726
Silgan Holdings
SLGN
$4.46B
| $972K | ﹤0.01% |
38,240
+8,400
| +28% | +$208K |
|
|
VR
1727
DELISTED
Validus Hold Ltd
VR
| $971K | ﹤0.01% |
25,400
| – | – |
|
1728
Cinemark Holdings
CNK
$4.3B
| $965K | ﹤0.01% |
27,300
| – | – |
|
1729
Tanger
SKT
$4.41B
| $964K | ﹤0.01% |
27,580
| – | – |
|
1730
Globus Medical
GMED
$11.5B
| $958K | ﹤0.01% |
40,061
-136,488
| -77% | -$3.29M |
|
|
AXLL
1731
DELISTED
AXIALL CORP COM STK (DE)
AXLL
| $950K | ﹤0.01% |
20,100
+2,600
| +15% | +$120K |
|
|
EFII
1732
DELISTED
Electronics for Imaging
EFII
| $949K | ﹤0.01% |
21,000
| – | – |
|
1733
Mercury Insurance
MCY
$5.82B
| $945K | ﹤0.01% |
20,093
+4,300
| +27% | +$202K |
|
1734
Ryman Hospitality Properties
RHP
$7.92B
| $943K | ﹤0.01% |
19,589
| – | – |
|
|
CVG
1735
DELISTED
Convergys
CVG
| $941K | ﹤0.01% |
43,900
| – | – |
|
1736
Cracker Barrel
CBRL
$1.28B
| $936K | ﹤0.01% |
9,400
| – | – |
|
|
CTB
1737
DELISTED
Cooper Tire & Rubber Co.
CTB
| $933K | ﹤0.01% |
31,100
+4,200
| +16% | +$114K |
|
1738
SPDR Gold Trust
GLD
$143B
| $928K | ﹤0.01% |
7,250
| – | – |
|
|
ECOM
1739
DELISTED
CHANNELADVISOR CORPORATION
ECOM
| $915K | ﹤0.01% |
34,706
-61,418
| -64% | -$1.56M |
|
1740
Hancock Whitney
HWC
$6.4B
| $913K | ﹤0.01% |
25,860
+2,000
| +8% | +$69K |
|
1741
Regal Rexnord
RRX
$11.7B
| $911K | ﹤0.01% |
11,600
-1,400
| -11% | -$106K |
|
1742
Carter's
CRI
$1.41B
| $910K | ﹤0.01% |
13,200
-300
| -2% | -$21.8K |
|
|
FMER
1743
DELISTED
FIRSTMERIT CORP
FMER
| $910K | ﹤0.01% |
46,076
-4,274
| -8% | -$83.6K |
|
1744
Idacorp
IDA
$8.26B
| $909K | ﹤0.01% |
15,710
+1,600
| +11% | +$88.4K |
|
1745
GATX Corp
GATX
$6.35B
| $907K | ﹤0.01% |
13,550
| – | – |
|
1746
TC Energy
TRP
$66.4B
| $904K | ﹤0.01% |
18,900
+3,900
| +26% | +$182K |
|
1747
Trustmark
TRMK
$2.8B
| $888K | ﹤0.01% |
35,949
+11,100
| +45% | +$265K |
|
|
RFMD
1748
DELISTED
RF MICRO DEVICES INC
RFMD
| $885K | ﹤0.01% |
92,248
| – | – |
|
|
SMLR
1749
DELISTED
Semler Scientific
SMLR
| $878K | ﹤0.01% |
212,677
+60
| +0% | +$279 |
|
|
WGL
1750
DELISTED
Wgl Holdings
WGL
| $878K | ﹤0.01% |
20,370
+1,118
| +6% | +$45K |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.